Since BRAF-mutated patients treated with PLX4032 have been reported to develop resistance after 6 months, we decided to investigate the effects induced by PLX4032 chronic treatment of BRAFV600E MeOV and BRAFV600D MeTA that are human metastatic melanoma cell lines derived from two patients. Here, BRAF is linked to metastatic melanoma.